Cargando…

P1375: SECOND PRIMARY MALIGNANCY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION

Detalles Bibliográficos
Autores principales:	Tan, T.-D., Chiou, L.-W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429460/ http://dx.doi.org/10.1097/01.HS9.0000848360.76227.29

Ejemplares similares

P1375: VENETOCLAX MODULATES TIM-3 EXPRESSION ON CD8 T CELLS IN ACUTE MYELOID LEUKEMIA PATIENTS
por: Ocadlikova, Darina, et al.
Publicado: (2023)

P568: COMPARISON OF VENETOCLAX-BASED INDUCTION THERAPY OR 3 + 7 FOLLOWED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR NEWLY DIAGNOSED AML PATIENTS
por: Tan, Tran-Der, et al.
Publicado: (2023)

1375. Characterization of Recurrent Central Line-associated Bloodstream Infections at Texas Children’s Hospital
por: Foster, Catherine, et al.
Publicado: (2020)

Brain CT scan results in Epileptic patients referred to neurologic clinics in Kermanshah in 1375-86
por: Afshari, Daryoosh, et al.
Publicado: (2012)

1375. Professional Status of Infectious Disease Specialists in Korea: A Nationwide Cross-sectional Study
por: Kim, Bongyoung, et al.
Publicado: (2021)

1077. Infectious complications after second allogeneic hematopoietic cell transplant (allo-HCT) in adult patients with hematological malignancies
por: Maurer, Stephen, et al.
Publicado: (2020)

P1334: THE IMPACT OF IMMUNOSUPPRESSION ON RECONSTITUTION OF CMV-SPECIFIC T CELLS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Dmitrova, A., et al.
Publicado: (2022)

P1336: ANTIVIRAL EXPOSURE TO GANCICLOVIR AND VALGANCICLOVIR IS NOT ASSOCIATED WITH INCREASED INCIDENCE OF RELAPSE OR SECONDARY MALIGNANCIES IN HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS
por: Duarte, D., et al.
Publicado: (2022)

SECOND MALIGNANCIES AFTER AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION IN CHILDREN
por: Danner-Koptik, Karina E, et al.
Publicado: (2012)

P1387: MONITORING OF DONOR CHIMERISM ON RED BLOOD CELLS ANTIGENS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Yovdiy, A., et al.
Publicado: (2022)

Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients
por: Rosenberg, A. S., et al.
Publicado: (2021)

P890: THE OUTCOME OF SECOND PRIMARY MALIGNANCIES DEVELOPING IN MM PATIENTS
por: Avivi, I., et al.
Publicado: (2022)

P1287: HETROMBOPAG FOR ENHANCEMENT OF PLATELET ENGRAFTMENT IN PATIENTS WITH LYMPHOMA AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Zhao, Linjun, et al.
Publicado: (2023)

P1297: CLINICAL PROGNOSTIC MODEL OF OSTEONECROSIS OF THE FEMORAL HEAD AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Yang, Bo, et al.
Publicado: (2023)

P1533: A PROGNOSTIC MODEL FOR PATIENTS WITH SEPTIC SHOCK AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Huang, Qiu-Sha, et al.
Publicado: (2023)

P1335: SECONDARY MALIGNANCIES AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION. SINGLE HOSPITAL EXPERIENCE.
por: Dorado López, A., et al.
Publicado: (2022)

P1256: IMPACT OF CRYOPRESERVATION OF PERIPHERAL BLOOD STEM CELLS FOR ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION ON HEMATOPOIETIC RECONSTITUTION: A SINGLE-CENTER EXPERIENCE.
por: Vida, Esther Maria Ortega, et al.
Publicado: (2023)

P1348: COMPARISON OF NATURAL KILLER CELL RECONSTITUTION AFTER HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION DEPENDING ON THE VARIANT OF T-CELL DEPLETION
por: Konova, Z., et al.
Publicado: (2022)

P1376: LENALIDOMIDE–BASED MAINTENANCE AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT FOR PATIENTS WITH HIGH RISK MULTIPLE MYELOMA
por: Pasvolsky, O., et al.
Publicado: (2022)

P1395: POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME AFTER PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: SINGLE-CENTER EXPERIENCE
por: Zhumatayev, S., et al.
Publicado: (2022)

P1263: SINGLE NUCLEOTIDE POLYMORPHISMS IN PATIENTS WITH ENDOTHELIAL DAMAGE AFTER PEDIATRIC ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Leimi, Lilli, et al.
Publicado: (2023)

P1617: CLINICAL SIGNIFICANCE OF CYTOMEGALOVIRUS DRUG RESISTANCE GENE MUTATIONS IN CYTOMEGALOVIRUS INFECTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: yang, D., et al.
Publicado: (2022)

A new 1.375-approximation algorithm for sorting by transpositions
por: Silva, Luiz Augusto G., et al.
Publicado: (2022)

1375. Strengthening Global Capacity to Detect Antimicrobial Resistance Threats
por: Benoit, Tina, et al.
Publicado: (2023)

P1303: DARATUMUMAB-BASED MAINTENANCE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA AFTER SALVAGE AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Pasvolsky, Oren, et al.
Publicado: (2023)

P1397: THIRD-PARTY MULTIVIRUS-SPECIFIC T CELLS FOR THE TREATMENT OF REFRACTORY VIRAL INFECTIONS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Yalcin, Koray, et al.
Publicado: (2023)

P1258: A CO-REACTIVATION MODEL OF DOUBLE-STRANDED DNA VIRUS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WAS CONSTRUCTED TO PREDICT THE MORTALITY AFTER TRANSPLANTATION
por: Ren, Jinhua, et al.
Publicado: (2023)

P1266: THE SKIRT CALCULATOR DYNAMICALLY TRACKS IMMUNE RECONSTITUTION AND PREDICTS CLINICAL OUTCOME AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Cao, Yigeng, et al.
Publicado: (2023)

P1325: EFFICACY AND SAFETY OF HEROMBOPAG FOR THE TREATMENT OF SECONDARY FAILURE OF PLATELET RECOVERY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Wang, Lu, et al.
Publicado: (2023)

P1357: IMPAIRED CELLULAR RESPONSES AGAINST SARS-COV-2 AFTER COVID-19 INFECTION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS
por: Mamez, A.-C., et al.
Publicado: (2022)

P1351: CHARACTERIZING ALLOGENEIC STEM CELL TRANSPLANTATION SAFETY IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES AFTER PEMBROLIZUMAB THERAPY
por: Kuruvilla, J., et al.
Publicado: (2022)

1375. Laboratory Abnormalities Among Patients with Pulmonary Mycobacterium avium Complex Infections
por: Varley, Cara D, et al.
Publicado: (2019)

P1365: DONOR LYMPHOCYTE INFUSION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: RESULTS FROM A RETROSPECTIVE STUDY
por: Rochate, D., et al.
Publicado: (2022)

P1394: DIFFERENT DOSES OF ANTITHYMOCYTE GLOBULIN (ATG) AS PART OF THE PREPARATIVE REGIMEN IN HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
por: Zhou, S., et al.
Publicado: (2022)

P1396: CD33-DELETED HEMATOPOIETIC STEM AND PROGENITOR CELLS DISPLAY NORMAL ENGRAFTMENT AFTER HEMATOPOIETIC CELL TRANSPLANT (HCT) AND TOLERATE POST-HCT GEMTUZUMAB OZOGAMICIN (GO) WITHOUT CYTOPENIAS
por: Koehne, Guenther, et al.
Publicado: (2023)

P1613: SINGLE-CELL ANALYSIS FOLLOWING SARS-COV-2 MRNA VACCINE IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS
por: Tranter, E., et al.
Publicado: (2022)

Prognostic factors of second hematopoietic allogeneic stem cell transplantation among hematological malignancy patients relapsed after first hematopoietic stem cell transplantation: A single center study
por: Lu, Yue, et al.
Publicado: (2023)

P1383: EXTRAMEDULLARY RELAPSE OF ACUTE MYELOID LEUKEMIA AND ACUTE LYMPHOBLASTIC LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION - A SINGLE-CENTER EXPERIENCE
por: Vasconcelos, F., et al.
Publicado: (2022)

P1322: EFFECTS OF DONOR-SPECIFIC ANTI-HLA ANTIBODIES (DSA) FOR PRIMARY GRAFT FAILURE OF HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THALASSEMIA MAJOR
por: Liao, Jianyun, et al.
Publicado: (2023)

Growth after hematopoietic stem cell transplantation in children with acute myeloid leukemia
por: Chung, Seung Joon, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_0c2t0fnj6sfh466u9q843sgv79